Dynavax Technologies (NASDAQ:DVAX) Director Buys $41,116.00 in Stock

Key Points

• Director Scott Dunseth Myers purchased 3,800 shares of Dynavax Technologies at an average price of $10.82 per share, increasing their ownership by 12.18%.
• Dynavax Technologies reported a $0.14 EPS for the last quarter, exceeding the estimated $0.12 EPS, with revenues of $95.44 million.
• Analysts have a consensus rating of "Moderate Buy" for DVAX, with an average price target of $24.33 based on recent research reports.

Dynavax Technologies Corporation (NASDAQ:DVAX - Get Free Report) Director Scott Dunseth Myers acquired 3,800 shares of Dynavax Technologies stock in a transaction dated Friday, August 22nd. The shares were bought at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the transaction, the director owned 35,004 shares of the company's stock, valued at approximately $378,743.28. The trade was a 12.18% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Dynavax Technologies Price Performance

NASDAQ DVAX traded down $0.1420 on Monday, reaching $10.3580. The company had a trading volume of 663,963 shares, compared to its average volume of 2,081,450. The firm's 50 day moving average price is $10.60 and its 200 day moving average price is $11.38. Dynavax Technologies Corporation has a 12 month low of $9.22 and a 12 month high of $14.63. The stock has a market capitalization of $1.21 billion, a PE ratio of -22.53 and a beta of 1.09. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The business had revenue of $95.44 million during the quarter, compared to the consensus estimate of $87.55 million. As a group, equities analysts predict that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Wall Street Analyst Weigh In

DVAX has been the subject of several research reports. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. JMP Securities restated a "market outperform" rating and set a $32.00 target price on shares of Dynavax Technologies in a research report on Friday. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $24.33.

Institutional Trading of Dynavax Technologies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. Envestnet Asset Management Inc. raised its position in Dynavax Technologies by 20.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 16,162 shares of the biopharmaceutical company's stock worth $206,000 after purchasing an additional 2,796 shares during the period. Russell Investments Group Ltd. increased its position in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 1,169 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Dynavax Technologies during the fourth quarter worth approximately $192,000. First Trust Advisors LP purchased a new position in shares of Dynavax Technologies during the fourth quarter worth approximately $847,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Dynavax Technologies by 4.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock worth $51,948,000 after acquiring an additional 171,933 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.